Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
August 4, 2022 08:00 AM EDTUpdated 01:59 PM
R&D

Am­gen chief Brad­way nabs a rare dis­ease play­er in $4B buy­out as the M&A tem­po ac­cel­er­ates

John Carroll

Editor & Founder

Am­gen CEO Bob Brad­way is bel­ly­ing up to the M&A ta­ble to­day, scoop­ing up the new­ly anoint­ed com­mer­cial biotech Chemo­Cen­tryx $CCXI and its re­cent­ly ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times